Byd Electronic Obtains Production License for E-Cigarettes in China

Aug.05.2022
BYD's subsidiary has obtained an e-cigarette manufacturing license, indicating its legal participation in the industry and potential competition.

In the past two years, with the successive release of new policies on electronic cigarette regulation, enterprises engaged in the production and operation of electronic cigarette products, vaporizers, and nicotine used in electronic cigarettes are required to obtain a production license, leading to some domestic electronic cigarette companies turning into the mainstream, and the electronic cigarette industry is moving towards a healthy and orderly development. Recently, BYD announced that it has obtained a production license, which means that BYD Electronics has officially participated in competition in the field of electronic cigarette OEMs with a legal identity.


BYD Electronics receives production license.


On August 4th, BYD Electronic announced on their official public account that their wholly-owned subsidiary, BYD Precision Manufacturing Co., Ltd., has been awarded a production license (for electronic cigarette processing enterprises) by the National Tobacco Monopoly Bureau. This means that BYD Electronic can now legally compete in the field of electronic cigarette processing.


BYD Electronic has announced that the company has completed the patent layout and automated production line for its full range of electronic atomization products. The company has integrated its own capabilities in new materials research and development, precision molds, product design and development, as well as intelligent manufacturing, with the goal of becoming a leader and practitioner in the field of health and harm reduction.


For A-share investors, BYD is best known for its new energy vehicles, to the extent that many people consider it to be just an auto company.


It is understood that BYD Electronic spun off from BYD and mainly engages in contract manufacturing of intelligent phones, masks, and e-cigarettes. As early as 2018, BYD Electronic has been laying out the e-cigarette business, and officially launched its ceramic atomization core (ceramic core) technology brand "BEEMCORE" in 2021.


It is worth mentioning that, on the morning of August 4th, BYD Electronic announced that it had been awarded a license to produce tobacco monopolies, and its stock price rose more than 12% at one point during the day, indicating the capital market's expectation for its electronic cigarette business.


Simaole's dominant market position may be challenged.


Aside from BYD Electronics, on the same day, SMIC announced on its official WeChat account, "SMIC Technology," that three fully-owned subsidiaries under the SMIC Group, Shenzhen McWalters Technology Co., Ltd., Shenzhen McBrother Technology Co., Ltd., and Shenzhen Weiplus Technology Co., Ltd., have been awarded the Tobacco Monopoly Bureau's production permits for tobacco monopoly enterprises. The issuance of these permits further strengthens SMIC's confidence in its future development, and the overall production and operation of the group will proceed according to the planned schedule.


It is undeniable that Smoore is currently the leading electronic cigarette company in China and even globally, and many institutions have high expectations for its development.


It is reported that in 2021, Smoore's global market share continued to expand to 22.8%, surpassing the total of the second to fifth places, and maintaining its position as the world's largest electronic atomization device manufacturer. However, Smoore's stock price has recently dropped significantly as investors believe that BYD and Luxshare Precision's entry into the industry will divide Smoore's market share and reduce their profitability.


However, industry insiders estimate that BYD's outsourcing capacity will not be too high, mainly because they are new to the industry and approved production capacity is mainly based on past business data. Some insiders have disclosed that the approved quantity for the pod is very low.


According to the "Regulations on the Management of Electronic Cigarettes" and related Q&A issued by the China National Tobacco Authority on March 11, 2022, anyone engaged in the production, wholesale, or retail of electronic cigarettes in China must obtain the relevant tobacco monopoly license. The regulations also specify that there will be a transition period from May 1, 2022 to September 30, 2022.


Starting from June, the government began conducting qualification and production capacity audits, which will continue until early October. This means that the production licenses and production capacity status of e-cigarette companies will be intensively disclosed in August and September. It is understood that both brand owners and factories are required to disclose their approved production capacity status.


Currently, it is a critical moment for license issuance. It is understood that regulatory agencies have established numerous teams to visit companies and conduct different types of inspections based on the industry. For example, for aerosol companies, the focus is on the completeness of licenses, compliance with site regulations, scientific manufacturing processes, quality control requirements, employee training and vocational education, as well as annual production capacity and sales history.


BYD Electronic stated that it will firmly support the national policies related to electronic cigarettes, operate its production in compliance with laws and regulations, and make positive contributions to the healthy and orderly development of the industry.


Simoer stated that in the future, they will continue to adhere to regulatory requirements and promote standardized, orderly development. They will also firmly support related national policies and operate in compliance with the law. Simultaneously, they will use scientific and technological innovation as the driving force for enterprise development, actively promote the long-term, healthy development of the industry, serve global customers and users, and fulfill their corporate responsibilities to contribute positively to society.


This article contains excerpts or reproductions of third-party information and its copyright belongs to the original media and author. If there is any infringement, please contact us for deletion. Any unit or individual who needs to reprint, please contact the author and do not reprint directly.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Ireland Raises Nicotine Product Taxes Again as Cigarettes Gain €1 and Vape Duty Is Set to Jump 40%
Ireland Raises Nicotine Product Taxes Again as Cigarettes Gain €1 and Vape Duty Is Set to Jump 40%
Ireland has increased tobacco excise under Budget 2027 and announced a further rise in its E-liquid Products Tax. From Oct. 7, the tax burden on a pack of 20 cigarettes in the most popular price category increased by €1, with pro-rata increases on other tobacco products. The government plans to raise EPT from €0.50 to €0.70 per millilitre from Jan. 1, 2027, a 40% increase applying to both nicotine-containing and nicotine-free e-liquids. The tobacco duty increase is expected to raise about €63.1 million in a full year.
Regulations
Oct.09
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden's Public Health Agency has found ingredient labels on ZYN nicotine pouches sold by Philip Morris International subsidiary Swedish Match to be noncompliant, according to Dagens industri. The products' packaging listed 10 to 13 ingredients, compared with 11 to 42 in regulatory submissions, with multiple flavoring ingredients grouped under the generic term "aromer." The agency ordered corrective action, warning of a conditional penalty of SEK 2 million per month for noncompliance. The order applies only to products manufactured after the decision becomes legally effective and does not require recalls. Swedish Match disputes the agency's interpretation and plans to appeal.
PMI
Oct.22
Turning Point Brands Q3 Modern Oral Net Sales Rise 103% to $74.4 Million as Attributable Profit Falls 81%
Turning Point Brands Q3 Modern Oral Net Sales Rise 103% to $74.4 Million as Attributable Profit Falls 81%
Turning Point Brands (TPB) reported third-quarter 2026 Modern Oral net sales of $74.4 million on November 9, up 102.9% year over year and representing 49.2% of consolidated net sales. Total company net sales rose 27.0% to $151.1 million, while net income attributable to TPB declined 81.4% to $3.93 million. The company is expanding the US retail presence of its FRE and ALP nicotine pouch brands and expects its Modern Oral chain-store footprint to grow by more than 70% during 2026. Selling, general and administrative expenses increased 69.1% to $75.3 million, while PMTA-related expenses reached approximately $3.15 million and manufacturing start-up costs totaled about $593,000. ALP plans to open a branded pop-up in New York City's SoHo neighborhood on November 13, alongside a marketing campaign extending into January 2027. TPB owns 50% of ALP but consolidates the venture in its financial statements.
company
Nov.11
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Technology reported FY2026 revenue of about $96 million, down 24.7% year over year, as U.S. cannabis-vapor hardware and European e-cigarette sales declined by $17.4 million and $12.7 million, respectively. Fourth-quarter revenue rose 32.5% to $26.7 million, while quarterly gross margin fell to 6.3%. For FY2027, the company is prioritizing Malaysia manufacturing and vapor ODM while continuing to develop nicotine pouches, IKE Tech age-verification technology and G-Mesh licensing. Ispire has not separately disclosed the revenue or profit contribution of those newer businesses.
Regulations
Sep.17 by 2Firsts Perspectives
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
FDA CTP Director Bret Koplow used his FDLI keynote in Washington to outline how the agency is rethinking the PMTA framework. He discussed category-specific review, nicotine pouch and sPMTA pilots, AI-assisted review, a 70% reduction in pending applications, and a major staffing constraint: CTP currently has only nine scientific review teams. He also reaffirmed tobacco harm reduction while stressing youth protection, flavored products, risk communication, and the challenge of unauthorized e-cigarettes.
Regulations
Oct.06